Form 8-K · Current Report · Filed 2024-05-02
Twist Bioscience Reports 25% Revenue Increase and Raises Guidance for FY 2024
Twist Bioscience Corporation reported a 25% increase in revenue for the second quarter of fiscal 2024, reaching $75.3 million, compared to $60.2 million in the same period last year.
- Filer
- Twist Bioscience Corporation TWST · NASDAQ
- Filed
- Accession
- 0001628280-24-019999
- CIK
- 0001581280
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
The company also saw a 45% growth in orders, totaling $93.2 million. Moreover, Twist Bioscience has raised its full-year revenue guidance for 2024 to a range of $300 million to $304 million and gross margin guidance to 41.5% to 42.0%.
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$31.96
Next session
+28.9%
Since filing
+386.7%
Latest close
$155.56
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from TWST reporting the same item, with the next session's move:
Exhibits (1)
About Twist Bioscience Corporation
Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.
Never miss another TWST filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.